Thyroid cancer gender disparity

Bibliography

• 1  Cerfolio RJ, Bryant AS, Scott E et al.: Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest130,1796–1802 (2006).
  MedlineGoogle Scholar
• 2  Kilfoy BA, Devesa SS, Ward MH et al.: Gender is an age-specific effect modifier for papillary cancers of the thyroid gland. Cancer Epidemiol. Biomarkers Prev.18,1092–1100 (2009).
  MedlineGoogle Scholar
• 3  Naugler WE, Sakurai T, Kim S et al.: Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science317,121–124 (2007).
  Medline CASGoogle Scholar
• 4  Ortega J, Sala C, Flor B, Lledo S: Efficacy and cost–effectiveness of the UltraCision harmonic scalpel in thyroid surgery: an analysis of 200 cases in a randomized trial. J. Laparoendosc. Adv. Surg. Tech. A14,9–12 (2004).
  MedlineGoogle Scholar
• 5  Soresi M, Giannitrapani L, D’Antona F et al.: Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J. Gastroenterol.12,2563–2568 (2006).
  Medline CASGoogle Scholar
• 6  Chen AY, Jemal A, Ward EM: Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer115,3801–3807 (2009).
  MedlineGoogle Scholar
• 7  Dal Maso L, Bosetti C, La Vecchia C, Franceschi S: Risk factors for thyroid cancer: an epidemiological review focused on nutritional factors. Cancer Causes Control20,75–86 (2009).
  MedlineGoogle Scholar
• 8  Gilliland FD, Hunt WC, Morris DM, Key CR: Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973–1991. Cancer79,564–573 (1997).
  Medline CASGoogle Scholar
• 9  Moysich KB, Menezes RJ, Michalek AM: Chernobyl-related ionising radiation exposure and cancer risk: an epidemiological review. Lancet Oncol.3,269–279 (2002).
  MedlineGoogle Scholar
• 10  Cardis E, Kesminiene A, Ivanov V et al.: Risk of thyroid cancer after exposure to 131I in childhood. J. Natl Cancer Inst.97,724–732 (2005).
  MedlineGoogle Scholar
• 11  Ron E, Lubin JH, Shore RE et al.: Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat. Res.141,259–277 (1995).
  Medline CASGoogle Scholar
• 12  Delange F, Lecomte P: Iodine supplementation: benefits outweigh risks. Drug Saf.22,89–95 (2000).
  Medline CASGoogle Scholar
• 13  Horn-Ross PL, Morris JS, Lee M et al.: Iodine and thyroid cancer risk among women in a multiethnic population: the Bay Area Thyroid Cancer Study. Cancer Epidemiol. Biomarkers Prev.10,979–985 (2001).
  Medline CASGoogle Scholar
• 14  Horn-Ross PL, Hoggatt KJ, Lee MM: Phytoestrogens and thyroid cancer risk: the San Francisco Bay Area thyroid cancer study. Cancer Epidemiol. Biomarkers Prev.11,43–49 (2002).
  Medline CASGoogle Scholar
• 15  Bosetti C, Kolonel L, Negri E et al.: A pooled analysis of case–control studies of thyroid cancer. VI. Fish and shellfish consumption. Cancer Causes Control12,375–382 (2001).
  Medline CASGoogle Scholar
• 16  Bosetti C, Negri E, Kolonel L et al.: A pooled analysis of case–control studies of thyroid cancer. VII. Cruciferous and other vegetables (International). Cancer Causes Control13,765–775 (2002).
  MedlineGoogle Scholar
• 17  Shibru D, Chung KW, Kebebew E: Recent developments in the clinical application of thyroid cancer biomarkers. Curr. Opin. Oncol.20,13–18 (2008).
  Medline CASGoogle Scholar
• 18  Trovisco V, Soares P, Preto A, Castro P, Maximo V, Sobrinho-Simoes M: Molecular genetics of papillary thyroid carcinoma: great expectations. Arq. Bras. Endocrinol. Metabol.51,643–653 (2007).
  MedlineGoogle Scholar
• 19  Garnett MJ, Marais R: Guilty as charged: B-RAF is a human oncogene. Cancer Cell6,313–319 (2004).
  Medline CASGoogle Scholar
• 20  Brzezianska E, Pastuszak-Lewandoska D, Wojciechowska K et al.: Investigation of V600E BRAF mutation in papillary thyroid carcinoma in the Polish population. Neuro. Endocrinol. Lett.28,351–359 (2007).
  Medline CASGoogle Scholar
• 21  Frasca F, Nucera C, Pellegriti G et al.: BRAF (V600E) mutation and the biology of papillary thyroid cancer. Endocr. Relat. Cancer15,191–205 (2008).
  Medline CASGoogle Scholar
• 22  Fugazzola L, Mannavola D, Cirello V et al.: BRAF mutations in an Italian cohort of thyroid cancers. Clin. Endocrinol. (Oxf.)61,239–243 (2004).
  Medline CASGoogle Scholar
• 23  Fugazzola L, Puxeddu E, Avenia N et al.: Correlation between B-RAF V600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr. Relat. Cancer13,455–464 (2006).
  Medline CASGoogle Scholar
• 24  Lee JH, Lee ES, Kim YS: Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis. Cancer110,38–46 (2007).
  MedlineGoogle Scholar
• 25  Lee X, Gao M, Ji Y et al.: Analysis of differential BRAF (V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann. Surg. Oncol16,240–245 (2009).
  MedlineGoogle Scholar
• 26  Liu RT, Chen YJ, Chou FF et al.: No correlation between BRAF V600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin. Endocrinol. (Oxf.)63,461–466 (2005).
  MedlineGoogle Scholar
• 27  Lupi C, Giannini R, Ugolini C et al.: Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J. Clin. Endocrinol. Metab.92,4085–4090 (2007).
  Medline CASGoogle Scholar
• 28  Trovisco V, Soares P, Preto A et al.: Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients’ age but not with tumour aggressiveness. Virchows Arch.446,589–595 (2005).
  Medline CASGoogle Scholar
• 29  Kim TY, Kim WB, Rhee YS et al.: The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin. Endocrinol. (Oxf.)65,364–368 (2006).
  Medline CASGoogle Scholar
• 30  Nakayama H, Yoshida A, Nakamura Y et al.: Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res.27,3645–3649 (2007).
  Medline CASGoogle Scholar
• 31  Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA: High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res.63,4561–4567 (2003).
  Medline CASGoogle Scholar
• 32  Fagin JA: Genetics of papillary thyroid cancer initiation: implications for therapy. Trans. Am. Clin. Climatol. Assoc.116,259–269; discussion 269–271 (2005).
  MedlineGoogle Scholar
• 33  Sadetzki S, Calderon-Margalit R, Modan B, Srivastava S, Tuttle RM: Ret/PTC activation in benign and malignant thyroid tumors arising in a population exposed to low-dose external-beam irradiation in childhood. J. Clin. Endocrinol. Metab.89,2281–2289 (2004).
  Medline CASGoogle Scholar
• 34  Basolo F, Molinaro E, Agate L et al.: RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma. Eur. J. Endocrinol.145,599–604 (2001).
  Medline CASGoogle Scholar
• 35  Brzezianska E, Karbownik M, Migdalska-Sek M, Pastuszak-Lewandoska D, Wloch J, Lewinski A: Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population. Mutat. Res.599,26–35 (2006).
  Medline CASGoogle Scholar
• 36  Puxeddu E, Moretti S, Giannico A et al.: Ret/PTC activation does not influence clinical and pathological features of adult papillary thyroid carcinomas. Eur. J. Endocrinol.148,505–513 (2003).
  Medline CASGoogle Scholar
• 37  Collins BJ, Chiappetta G, Schneider AB et al.: RET expression in papillary thyroid cancer from patients irradiated in childhood for benign conditions. J. Clin. Endocrinol. Metab.87,3941–3946 (2002).
  Medline CASGoogle Scholar
• 38  Elisei R, Romei C, Vorontsova T et al.: RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults. J. Clin. Endocrinol. Metab.86,3211–3216 (2001).
  Medline CASGoogle Scholar
• 39  Rabes HM, Demidchik EP, Sidorow JD et al.: Pattern of radiation-induced RET and NTRK1 rearrangements in 191 post-Chernobyl papillary thyroid carcinomas: biological, phenotypic, and clinical implications. Clin. Cancer Res.6,1093–1103 (2000).
  Medline CASGoogle Scholar
• 40  Tuttle RM, Lukes Y, Onstad L et al.: Ret/PTC activation is not associated with individual radiation dose estimates in a pilot study of neoplastic thyroid nodules arising in Russian children and adults exposed to Chernobyl fallout. Thyroid18,839–846 (2008).
  Medline CASGoogle Scholar
• 41  Moses W, Weng J, Khanafshar E, Duh QY, Clark OH, Kebebew E: Multiple genetic alterations in papillary thyroid cancer are associated with younger age at presentation. J. Surg. Res.160,179–183 (2010).
  Medline CASGoogle Scholar
• 42  Negri E, Dal Maso L, Ron E et al.: A pooled analysis of case–control studies of thyroid cancer. II. Menstrual and reproductive factors. Cancer Causes Control10,143–155 (1999).
  Medline CASGoogle Scholar
• 43  Brindel P, Doyon F, Rachedi F et al.: Menstrual and reproductive factors in the risk of differentiated thyroid carcinoma in native women in French Polynesia: a population-based case–control study. Am. J. Epidemiol.167,219–229 (2008).
  MedlineGoogle Scholar
• 44  Mack WJ, Preston-Martin S, Bernstein L, Qian D, Xiang M: Reproductive and hormonal risk factors for thyroid cancer in Los Angeles County females. Cancer Epidemiol. Biomarkers Prev.8,991–997 (1999).
  Medline CASGoogle Scholar
• 45  Pham TM, Fujino Y, Mikami H et al.: Reproductive and menstrual factors and thyroid cancer among Japanese women: the Japan Collaborative Cohort Study. J. Womens Health (Larchmt)18,331–335 (2009).
  MedlineGoogle Scholar
• 46  Sakoda LC, Horn-Ross PL: Reproductive and menstrual history and papillary thyroid cancer risk: the San Francisco Bay Area thyroid cancer study. Cancer Epidemiol. Biomarkers Prev.11,51–57 (2002).
  MedlineGoogle Scholar
• 47  Truong T, Orsi L, Dubourdieu D, Rougier Y, Hemon D, Guenel P: Role of goiter and of menstrual and reproductive factors in thyroid cancer: a population-based case–control study in New Caledonia (South Pacific), a very high incidence area. Am. J. Epidemiol.161,1056–1065 (2005).
  MedlineGoogle Scholar
• 48  Yager JD, Liehr JG: Molecular mechanisms of estrogen carcinogenesis. Annu. Rev. Pharmacol. Toxicol.36,203–232 (1996).
  Medline CASGoogle Scholar
• 49  Lee ML, Chen GG, Vlantis AC, Tse GM, Leung BC, van Hasselt CA: Induction of thyroid papillary carcinoma cell proliferation by estrogen is associated with an altered expression of Bcl-xL. Cancer J.11,113–121 (2005).
  Medline CASGoogle Scholar
• 50  Rebai M, Kallel I, Charfeddine S, Hamza F, Guermazi F, Rebai A: Association of polymorphisms in estrogen and thyroid hormone receptors with thyroid cancer risk. J. Recept. Signal Transduct. Res.29,113–118 (2009).
  MedlineGoogle Scholar
• 51  Inoue H, Oshimo K, Miki H, Kawano M, Monden Y: Immunohistochemical study of estrogen receptors and the responsiveness to estrogen in papillary thyroid carcinoma. Cancer72,1364–1368 (1993).
  Medline CASGoogle Scholar
• 52  Zeng Q, Chen GG, Vlantis AC, van Hasselt CA: Oestrogen mediates the growth of human thyroid carcinoma cells via an oestrogen receptor-ERK pathway. Cell Prolif.40,921–935 (2007).
  Medline CASGoogle Scholar
• 53  Zeng Q, Chen G, Vlantis A, Tse G, van Hasselt C: The contributions of oestrogen receptor isoforms to the development of papillary and anaplastic thyroid carcinomas. J. Pathol.214,425–433 (2008).
  Medline CASGoogle Scholar
• 54  Rajoria S, Suriano R, Shanmugam A et al.: Metastatic phenotype is regulated by estrogen in thyroid cells. Thyroid20,33–41 (2010).
  Medline CASGoogle Scholar
• 55  Yoshimura M, Hershman JM: Thyrotropic action of human chorionic gonadotropin. Thyroid5,425–434 (1995).
  Medline CASGoogle Scholar
• 56  Knudsen N, Laurberg P, Perrild H, Bulow I, Ovesen L, Jorgensen T: Risk factors for goiter and thyroid nodules. Thyroid12,879–888 (2002).
  MedlineGoogle Scholar
• 57  Kung AW, Chau MT, Lao TT, Tam SC, Low LC: The effect of pregnancy on thyroid nodule formation. J. Clin. Endocrinol. Metab.87,1010–1014 (2002).
  Medline CASGoogle Scholar
• 58  Vannucchi G, Perrino M, Rossi S et al.: Clinical and molecular features of differentiated thyroid cancer diagnosed during pregnancy. Eur. J. Endocrinol.162,145–151 (2010).
  Medline CASGoogle Scholar
• 101  National Cancer Institute: Surveillance, Epidemiology and End Results (SEER) Program www.seer.cancer.gov
  Google Scholar